Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting state Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

NCT04303039
View directory record Official record
Conditions
Gout, Food-drug Interaction
Interventions
ABP-671
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

NCT03095638
View directory record Official record
Conditions
HIV Infections
Interventions
Conventional dolutegravir 10 mg tablet, Conventional dolutegravir 50 mg tablet, Dispersible dolutegravir 5 mg tablet, Conventional dolutegravir 25 mg tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

NCT02259179
View directory record Official record
Conditions
Healthy
Interventions
Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 20, 2026, 1:54 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

NCT01537497
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

NCT01322438
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (BAY73-4506) + rifampin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

NCT01682408
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers

NCT04156646
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Balovaptan, Esomeprazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

NCT04757974
View directory record Official record
Conditions
HIV Infections
Interventions
Fostemsavir 600 mg, Fostemsavir 200 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

NCT00585468
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

NCT02372383
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ethambutol, Rifampin, Azithromycin, Pancrelipase
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 20, 2026, 1:54 PM EDT
Not listed Early Phase 1 Interventional

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

NCT04203927
View directory record Official record
Conditions
Type2 Diabetes, Insulin Sensitivity
Interventions
Empagliflozin 25 MG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

NCT01511432
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-Effect Pharmacokinetic Study of PL2200

NCT01244100
View directory record Official record
Conditions
Healthy
Interventions
PL2200 fasted, PL2200 fed
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Early Phase 1 Interventional

Controlled Insulin Delivery: Combining Technology With Treatment

NCT01484457
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed-loop session
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States

NCT06309914
View directory record Official record
Conditions
Mental Processes, Cognitive Change, Mood Change
Interventions
Placebo, Enovita Grape Seed Extract, Mirtoselect Bilberry Extract, Virtiva Plus Ginko Biloba Extract
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
25 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 20, 2026, 1:54 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Manipulating the Gut Microbiome Study

NCT03181828
View directory record Official record
Conditions
Urea Cycle Disorder
Interventions
Acetohydroxamic Acid Oral Tablet, No treatment
Drug · Other
Lead sponsor
Nicholas Ah Mew
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 20, 2026, 1:54 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Dynamic Connectivity Under Metabolic Constraints

NCT04840095
View directory record Official record
Conditions
Insulin Resistance, Healthy, Diet Modification, Aging
Interventions
Ketones, Glucose
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 20, 2026, 1:54 PM EDT
Recruiting Not applicable Interventional

Mental Stress Reactivity in Women With CMD

NCT05401630
View directory record Official record
Conditions
Post-menopause
Interventions
Study Procedures
Other
Lead sponsor
Emory University
Other
Eligibility
45 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 20, 2026, 1:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

NCT04101045
View directory record Official record
Conditions
Type 1 Diabetes, De Novo Lipogenesis
Interventions
Oral Glucose Tolerance Test
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
13 Years to 22 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 20, 2026, 1:54 PM EDT
Recruiting Phase 1 Interventional

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT06789172
View directory record Official record
Conditions
Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions
OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
Drug · Combination Product · Other
Lead sponsor
Epkin
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Beverly Hills, California • Santa Monica, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Results available

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

NCT01898078
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
The Bronx, New York • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 20, 2026, 1:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

NCT00802074
View directory record Official record
Conditions
Healthy
Interventions
Raltegravir, Fosamprenavir, Ritonavir
Drug
Lead sponsor
Garden State Infectious Disease Associates, PA
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 20, 2026, 1:54 PM EDT